outbreak in china, page-2

merial excited Dr. Marcus Remmers, Head of Business Development at Merial, said, "We are very excited about the adenovirus vector as a potential delivery platform. Given the current results to date and significant increases in productivity evidenced from the initial trials, we believe the market potential for these products could be significant, both in terms of providing an alternative to in-feed antibiotics and safely improving profitability for producers."

Whilst the commercial terms relating to the Evaluation and Sublicense agreements are confidential, the Imugene Group will receive initially agreed payments from Merial. Milestone based sublicense fees and royalty payments will be paid following successful exercise of the sublicense.